Can You Legally Buy BPC-157 and Other Peptides? What the FDA Is Actually Considering

Peptide vials representing proposed FDA compounding policy changes in the United States

MEDISEARCHER NEWS
United States · Medication Regulation · 9 October 2026

In brief: The US Food and Drug Administration and Department of Health and Human Services have now formally submitted an “Interim Access Policy for Compounding Using Certain Peptides” for White House regulatory review. The policy could potentially expand access to some peptides through compounding pharmacies, but its text has not yet been published and it is not currently in effect. BPC-157, TB-500 and the other peptides involved have not become FDA-approved drugs.

Updated: 21 October 2026

Update: FDA peptide policy reaches White House review

Since this article was first published, the proposed peptide-access policy has moved from media reports into the formal federal regulatory process.

On October 14, 2026, HHS and FDA submitted an action titled “Interim Access Policy for Compounding Using Certain Peptides” to the White House Office of Information and Regulatory Affairs (OIRA). The official federal record identifies it as RIN 0910-ZD94 and lists its status as Pending Review.

On October 20, Health Secretary Robert F. Kennedy Jr. also publicly said that the administration wants to create a regulated marketplace for peptides, arguing that consumers are already obtaining them through a largely unregulated gray market.

The policy itself has not yet been published and is not in effect. Its precise scope, which peptides it will cover and what conditions pharmacies may have to meet therefore remain unknown. The peptides under consideration have also not become FDA-approved medicines.

What has actually changed?

When MediSearcher first published this article on October 9, the Trump administration was reportedly considering an interim policy that could expand access to certain peptides through compounding pharmacies, but no formal federal regulatory action implementing or advancing that proposal had been identified.

That has now changed.

The federal government’s regulatory review database shows that HHS and FDA submitted an action titled “Interim Access Policy for Compounding Using Certain Peptides” to the Office of Information and Regulatory Affairs on October 14.

The filing is identified as RIN 0910-ZD94, is classified at the “Notice” stage and is currently listed as Pending Review.

This is significant because it confirms that an actual FDA/HHS policy has progressed into formal White House regulatory review.

However, the public filing does not contain the text of the policy. It does not identify which peptides will ultimately be covered, specify the conditions that would apply to pharmacies or state when any new access pathway might begin.

Reports have indicated that BPC-157 is among the peptides that could be covered, but until the policy itself is published, its exact scope should not be treated as settled.

Nothing in the OIRA filing makes BPC-157 or the other peptides FDA-approved drugs, and the filing does not by itself authorize pharmacies to begin supplying them under a new federal access policy.

What did Robert F. Kennedy Jr. say about peptide access?

On October 20, 2026, US Health Secretary Robert F. Kennedy Jr. publicly discussed the administration’s approach to peptides during an interview on Fox News.

Kennedy said the administration’s objective is to establish a regulated marketplace because Americans are already purchasing peptides through existing gray-market channels.

He said the aim is to create a system in which consumers can have greater confidence that products contain what they claim to contain, are produced safely and come from inspected manufacturing facilities.

The comments provide clearer confirmation of the administration’s policy objective, but they do not change the current legal status of the products.

The proposed FDA interim access policy remains under White House review, its full text is not public and the peptides under consideration have not been approved by FDA as safe and effective drugs.

How did the peptide policy reach this point?

The current debate follows a two-day meeting of the FDA’s Pharmacy Compounding Advisory Committee (PCAC) on July 23 and 24, 2026.

The FDA’s official meeting record shows that seven peptide-related substances were considered for possible inclusion on the 503A Bulks List.

Peptide Use(s) evaluated by FDA Committee recommendation
BPC-157 Ulcerative colitis Recommended
KPV Wound healing and inflammatory conditions Recommended
TB-500 Wound healing Recommended
MOTS-c Obesity and osteoporosis Recommended
Semax Cerebral ischemia, migraine and trigeminal neuralgia Recommended
Epitalon Insomnia Recommended
Emideltide (DSIP) Opioid withdrawal, chronic insomnia and narcolepsy Not recommended

Important: the conditions in this table are the uses the FDA evaluated during the compounding review. They should not be read as FDA-approved indications or as evidence that the peptides have been proven safe and effective for those uses.

Did the FDA approve BPC-157 and the other peptides?

No.

This remains the most important distinction in the story.

The July meeting concerned whether particular bulk drug substances should be eligible for use in certain compounded drugs under Section 503A. It was not an FDA drug-approval process.

The advisory committee ultimately recommended six of the seven peptide-related substances. The recommendations were non-binding, and the FDA must make the relevant regulatory decisions.

The FDA’s own briefing material also shows an important detail that can be lost in simplified accounts of the vote: FDA staff had proposed that the peptide substances under review not be included on the 503A Bulks List. The advisory committee subsequently voted to recommend six of them despite those concerns.

The October submission of an interim access policy for White House review is another regulatory step. It does not convert the advisory committee recommendations into FDA drug approvals.

BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon have not become FDA-approved drugs as a result of either the July committee vote or the October policy submission.

What is the 503A Bulks List?

Section 503A of the Federal Food, Drug, and Cosmetic Act provides a framework under which qualifying state-licensed pharmacies, federal facilities and licensed physicians can compound drugs for individual patients.

According to the FDA’s Section 503A guidance, compounders generally may use a bulk drug substance if it:

  • complies with an applicable United States Pharmacopeia or National Formulary monograph, if one exists;
  • is a component of an FDA-approved drug product where an applicable monograph does not exist; or
  • appears on the FDA’s 503A Bulks List when the other conditions do not apply.

The FDA also requires bulk substances used under the provision to meet additional conditions, including requirements concerning certificates of analysis and manufacturing establishments.

Being placed on the 503A Bulks List therefore matters because it can create a route for a substance to be used in qualifying prescription compounding.

But inclusion on that list still does not mean the resulting compounded product is an FDA-approved drug.

What is “enforcement discretion”?

Enforcement discretion is central to understanding what the administration may be considering.

The FDA already uses interim enforcement policies while it evaluates some substances nominated for the 503A Bulks List. Under certain conditions, the agency may state that it does not intend to take enforcement action against qualifying compounders while a substance remains under evaluation.

The FDA describes this approach in its January 2025 interim policy on Section 503A bulk substances.

Enforcement discretion is not FDA approval. It is an agency policy describing circumstances in which FDA does not intend to take enforcement action even though the formal regulatory process has not been completed.

Reporting about the new peptide proposal indicates that an enforcement-discretion approach could be used to create temporary access through qualifying compounding pharmacies.

However, because the text of RIN 0910-ZD94 has not yet been made public, the precise mechanism, products covered and safeguards attached to the policy remain unknown.

Can you get BPC-157 from a compounding pharmacy now?

The October regulatory filing does not, by itself, create a new federal right to obtain BPC-157 or the other peptides.

The proposed policy remains under White House review and has not yet been published or put into effect.

Patients should therefore be cautious about websites or social-media posts claiming that BPC-157 or the other peptides are now “FDA approved,” “FDA legalized” or authorized for unrestricted sale because of the July committee vote or October policy submission.

If an interim policy is ultimately issued, its exact wording will matter. It could specify which substances are covered, which types of compounders can use them, whether particular routes of administration qualify and what prescribing, disclosure, reporting or other safeguards apply.

State pharmacy and medical rules may also continue to affect access.

A compounded drug is fundamentally different from an FDA-approved drug. FDA-approved products go through the agency’s approval process for safety, effectiveness and manufacturing quality. Compounded drugs are not FDA-approved in that way.

Why is the FDA concerned about compounded peptides?

The debate is not simply about whether patients should have access.

The FDA’s July meeting materials contain extensive reviews of the individual substances and the evidence available for their proposed uses.

Peptide manufacturing can also present particular quality challenges. FDA materials discuss issues such as peptide-related impurities, incomplete or truncated peptide sequences, aggregation and characterization of the active ingredient.

These concerns matter because products bought through gray-market websites may be marketed as peptides for human use without having gone through the approval and manufacturing controls required for FDA-approved medicines.

A recent Australian TGA investigation into unapproved peptides illustrates these risks: laboratory testing found no detectable TB-500 in several Synedica products and less retatrutide than claimed in others.

The FDA maintains a separate list of bulk drug substances that may present significant safety risks in compounding. It includes several other substances popular in the peptide and performance/wellness market, including GHRP-6, ibutamoren and ipamorelin.

The administration’s argument for a regulated peptide marketplace does not eliminate these scientific and manufacturing concerns. Rather, it reflects a policy argument that bringing some existing demand into a regulated pharmacy channel could provide greater oversight than leaving consumers to purchase products through an uncontrolled gray market.

Does this mean the FDA is opening the door to all peptides?

No.

The July committee considered seven specifically nominated peptide-related substances. Six received positive recommendations and one — emideltide, also known as DSIP — did not.

Other peptides and peptide-like substances have separate regulatory histories and cannot be assumed to have the same status.

For example, the FDA’s safety-risk material identifies potential concerns with some other substances used in compounding. For ipamorelin acetate, FDA cites concerns including potential immunogenicity associated with aggregation or peptide-related impurities. For ibutamoren mesylate, the agency identifies a potential congestive-heart-failure safety signal.

Those examples illustrate why a policy involving BPC-157, KPV, TB-500, MOTS-c, Semax or Epitalon would not amount to a general legalization or approval of “peptides.”

It is also important that the public OIRA record does not itself list the substances covered by the proposed interim policy. The final scope should therefore be confirmed from the policy itself once it is published.

Why consider broader access if the evidence is limited?

This is the central tension behind the policy debate.

Demand for peptides already exists, and many products are available through online sellers operating outside conventional prescription-pharmacy channels.

Kennedy’s October 20 comments make the administration’s reasoning clearer: rather than assuming that consumer demand will disappear, the administration wants to create a regulated marketplace in which product identity, manufacturing and facility standards can be more closely controlled.

Supporters of broader compounding access argue that bringing some existing demand into licensed pharmacies could provide more oversight than an uncontrolled gray market.

Critics argue that greater availability could expose more patients to substances for which evidence on safety and effectiveness remains limited and could give consumers the mistaken impression that the products have received conventional FDA approval.

The July advisory committee votes themselves show that this was not a straightforward scientific consensus. The committee recommended six peptides despite FDA staff recommending against their inclusion.

The question facing regulators is therefore not simply whether peptide use exists. It is whether a regulated compounding pathway can address existing demand without implying a level of safety or effectiveness that has not been established through the FDA drug-approval process.

What happens next?

The immediate next step is the White House regulatory review.

As of October 21, the Office of Information and Regulatory Affairs lists RIN 0910-ZD94 as Pending Review. The federal listing gives no legal deadline for completing that review.

Several important questions therefore remain unanswered:

  • Which peptides will the interim policy cover?
  • Will BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon all be included?
  • Which compounding pharmacies or other facilities will qualify?
  • Will access be restricted to particular formulations or routes of administration?
  • What prescribing requirements will apply?
  • Will pharmacies or prescribers have additional patient-disclosure or adverse-event-reporting obligations?
  • When will the policy take effect?

Those questions cannot be answered definitively until the policy is published.

The longer-term Section 503A regulatory process is also separate. The July advisory committee recommendations did not themselves place the six peptides on the 503A Bulks List.

Peptide regulation timeline

  • July 23–24, 2026: FDA’s Pharmacy Compounding Advisory Committee reviews seven peptide-related substances.
  • July 24: Six — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — receive positive committee recommendations. Emideltide/DSIP does not.
  • October 7: The Washington Post reports that the administration is considering interim enforcement discretion that could permit access to certain compounded peptides while longer-term rules are developed.
  • October 9: When MediSearcher first publishes this article, no implementing FDA policy has yet been identified.
  • October 14: HHS and FDA submit the “Interim Access Policy for Compounding Using Certain Peptides” to the White House Office of Information and Regulatory Affairs for review.
  • October 15: The federal regulatory filing becomes public, confirming that the proposed policy has formally entered White House review.
  • October 20: Health Secretary Robert F. Kennedy Jr. says the administration wants a regulated peptide marketplace intended to provide greater oversight of products consumers are already obtaining through gray-market channels.
  • October 21: RIN 0910-ZD94 remains listed as Pending Review. The policy text has not yet been published.

MediSearcher will continue to update this article when the White House review is completed, the FDA publishes the interim policy or the regulatory status of the individual peptides changes.

What patients should know

The immediate takeaway is simpler than the regulatory process behind it:

  • The FDA has not approved BPC-157, KPV, TB-500, MOTS-c, Semax or Epitalon through this process.
  • An FDA advisory committee recommended the six substances for the 503A compounding list in July.
  • The committee’s recommendations are not themselves final FDA action.
  • HHS and FDA have now formally submitted an interim peptide-compounding policy for White House regulatory review.
  • The policy remains under review and its full text has not been published.
  • The October filing does not by itself authorize unrestricted access to BPC-157 or other peptides.
  • Compounded drugs should not be confused with FDA-approved drugs.
  • Any future policy covering selected substances would not mean that all peptides have been approved or cleared for compounding.

Patients considering any compounded medication should discuss the potential benefits, risks and regulatory status with an appropriately licensed healthcare professional and verify that any pharmacy involved is properly licensed.

Frequently asked questions

Is BPC-157 FDA approved?

No. BPC-157 has not become an FDA-approved drug as a result of either the July 2026 advisory committee vote or the October submission of an interim access policy for White House review.

The committee recommended BPC-157-related bulk substances for possible inclusion on the 503A Bulks List used in pharmacy compounding. That is a different regulatory process from FDA drug approval.

Did the FDA legalize BPC-157 in 2026?

No. It would be misleading to describe the October development as FDA “legalizing” BPC-157.

FDA and HHS have submitted an interim policy concerning compounding with certain peptides for White House review, but the policy has not yet been published or put into effect.

Even if a future policy permits qualifying pharmacies to compound BPC-157 under specified conditions, that would not make BPC-157 an FDA-approved drug.

Is the new FDA peptide policy in effect?

No. As of October 21, 2026, the “Interim Access Policy for Compounding Using Certain Peptides” is listed by the federal Office of Information and Regulatory Affairs as Pending Review.

The policy text has not yet been published, so its precise scope and conditions are not currently known.

Which peptides did the FDA advisory committee recommend?

The committee recommended BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. It did not recommend emideltide, also known as DSIP.

Does a 503A recommendation mean a peptide is safe and effective?

No. A recommendation concerning eligibility for pharmacy compounding is not an FDA determination that a substance is safe and effective for a particular medical indication.

Will patients need a prescription?

Section 503A generally concerns patient-specific pharmacy compounding associated with prescriptions, but the exact conditions of the new interim peptide policy cannot be confirmed until the policy is published.

Patients should not assume that the White House review authorizes unrestricted or over-the-counter peptide sales.

When will the new peptide policy take effect?

There is currently no confirmed implementation date.

The federal regulatory record lists the proposal as Pending Review and gives no legal deadline for completion of the White House review. The policy would need to be issued before its precise effective date and conditions can be confirmed.


Reviewed by: Dr Mattias Hagman, PhD

Editorial review: This article was reviewed for source accuracy, regulatory context and consistency with MediSearcher’s editorial standards. The October update was checked against the federal Office of Information and Regulatory Affairs record for RIN 0910-ZD94, FDA materials concerning Section 503A and the July 2026 Pharmacy Compounding Advisory Committee meeting, and current reporting concerning the proposed interim peptide-access policy. The article distinguishes White House regulatory review, enforcement discretion, pharmacy compounding and conventional FDA drug approval.

Last reviewed: 21 October 2026

Sources and verification

MediSearcher reviewed the following primary regulatory material and reporting when preparing and updating this article:

This article is for informational purposes only and does not provide medical advice. The proposed interim peptide-compounding policy remains under White House review as of October 21, 2026 and its full text has not been published. Regulatory policies and the status of compounded drugs can change. Check current FDA information and consult an appropriately licensed healthcare professional before making treatment decisions.